{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:27:38Z","timestamp":1785522458753,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01791-6","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:20:04Z","timestamp":1781670004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies"],"prefix":"10.1007","volume":"28","author":[{"given":"Serafino","family":"LaGalbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia E.","family":"Metropulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle A.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Principe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"1791_CR1","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1182\/bloodadvances.2021004535","volume":"8","author":"JE Haydu","year":"2024","unstructured":"Haydu JE, Abramson JS. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas. Blood Adv. 2024;8:4700\u201310. https:\/\/doi.org\/10.1182\/bloodadvances.2021004535.","journal-title":"Blood Adv"},{"key":"1791_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/abt\/tbaf026","volume":"9","author":"X Kang","year":"2026","unstructured":"Kang X, Zhao Y, Ling H, Huang X. Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy. Antib Ther. 2026;9:58\u201369. https:\/\/doi.org\/10.1093\/abt\/tbaf026.","journal-title":"Antib Ther"},{"key":"1791_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s11899-021-00628-2","volume":"16","author":"M Schwerdtfeger","year":"2021","unstructured":"Schwerdtfeger M, et al. Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job. Curr Hematol Malig Rep. 2021;16:218\u201333. https:\/\/doi.org\/10.1007\/s11899-021-00628-2.","journal-title":"Curr Hematol Malig Rep"},{"key":"1791_CR4","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s11912-022-01272-6","volume":"24","author":"G Shouse","year":"2022","unstructured":"Shouse G, Danilov AV, Artz A. CAR T-Cell Therapy in the Older Person: Indications and Risks. Curr Oncol Rep. 2022;24:1189\u201399. https:\/\/doi.org\/10.1007\/s11912-022-01272-6.","journal-title":"Curr Oncol Rep"},{"key":"1791_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s00117-025-01472-8","volume":"65","author":"H Huber","year":"2025","unstructured":"Huber H, Leupolt E, Kundgen L, Bentz M. [Modern systemic treatment-bispecific antibodies and CAR-T cell therapy: Clinical management, mechanisms of action, outcomes]. Radiol (Heidelb). 2025;65:490\u20139. https:\/\/doi.org\/10.1007\/s00117-025-01472-8.","journal-title":"Radiol (Heidelb)"},{"key":"1791_CR6","doi-asserted-by":"publisher","first-page":"101628","DOI":"10.1016\/j.jgo.2023.101628","volume":"15","author":"OS Akhtar","year":"2024","unstructured":"Akhtar OS, et al. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis. J Geriatr Oncol. 2024;15:101628. https:\/\/doi.org\/10.1016\/j.jgo.2023.101628.","journal-title":"J Geriatr Oncol"},{"key":"1791_CR7","doi-asserted-by":"publisher","unstructured":"Verma V, Sharma G. Bispecific antibodies in clinical practice: Understanding recent advances and current place in cancer treatment landscape. Clin Exp Med. 2024;25. https:\/\/doi.org\/10.1007\/s10238-024-01520-y.","DOI":"10.1007\/s10238-024-01520-y"},{"key":"1791_CR8","doi-asserted-by":"publisher","unstructured":"Sayed A, et al. Cardiovascular toxicities associated with bispecific T-cell engager therapy. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2023-008518.","DOI":"10.1136\/jitc-2023-008518"},{"key":"1791_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11912-021-01068-0","volume":"23","author":"NP Patel","year":"2021","unstructured":"Patel NP, Doukas PG, Gordon LI, Akhter N. Cardiovascular Toxicities of CAR T-cell Therapy. Curr Oncol Rep. 2021;23:78. https:\/\/doi.org\/10.1007\/s11912-021-01068-0.","journal-title":"Curr Oncol Rep"},{"key":"1791_CR10","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1182\/bloodadvances.2024013849","volume":"8","author":"M Munir","year":"2024","unstructured":"Munir M, Sayed A, Addison D, Epperla N. Cardiovascular toxicities associated with novel cellular immune therapies. Blood Adv. 2024;8:6282\u201396. https:\/\/doi.org\/10.1182\/bloodadvances.2024013849.","journal-title":"Blood Adv"},{"key":"1791_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaccao.2023.07.009","volume":"5","author":"B Lefebvre","year":"2023","unstructured":"Lefebvre B, et al. Incidence of MACE in Patients Treated With CAR-T Cell Therapy: A Prospective Study. JACC CardioOncol. 2023;5:747\u201354. https:\/\/doi.org\/10.1016\/j.jaccao.2023.07.009.","journal-title":"JACC CardioOncol"},{"key":"1791_CR12","doi-asserted-by":"publisher","first-page":"102504","DOI":"10.1016\/j.eclinm.2024.102504","volume":"69","author":"F Korell","year":"2024","unstructured":"Korell F, et al. Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study. EClinicalMedicine. 2024;69:102504. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102504.","journal-title":"EClinicalMedicine"},{"key":"1791_CR13","doi-asserted-by":"publisher","first-page":"e2437222","DOI":"10.1001\/jamanetworkopen.2024.37222","volume":"7","author":"D Koeckerling","year":"2024","unstructured":"Koeckerling D, et al. Cardiovascular Events After Chimeric Antigen Receptor T-Cell Therapy for Advanced Hematologic Malignant Neoplasms: A Meta-Analysis. JAMA Netw Open. 2024;7:e2437222. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.37222.","journal-title":"JAMA Netw Open"},{"key":"1791_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40959-024-00252-y","volume":"10","author":"S Maleki","year":"2024","unstructured":"Maleki S, et al. Cardiac adverse events after Chimeric Antigen Receptor (CAR) T cell therapies: an updated systematic review and meta-analysis. Cardiooncology. 2024;10:52. https:\/\/doi.org\/10.1186\/s40959-024-00252-y.","journal-title":"Cardiooncology"},{"key":"1791_CR15","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/ejh.14289","volume":"113","author":"R Mazetto","year":"2024","unstructured":"Mazetto R, et al. The cardiotoxic effects of CAR-T cell therapy: An updated systematic review and meta-analysis. Eur J Haematol. 2024;113:798\u2013809. https:\/\/doi.org\/10.1111\/ejh.14289.","journal-title":"Eur J Haematol"},{"key":"1791_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s43856-024-00540-9","volume":"4","author":"B Karthikeyan","year":"2024","unstructured":"Karthikeyan B, et al. Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers. Commun Med (Lond). 2024;4:116. https:\/\/doi.org\/10.1038\/s43856-024-00540-9.","journal-title":"Commun Med (Lond)"},{"key":"1791_CR17","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/j.jacc.2020.02.070","volume":"75","author":"JE Salem","year":"2020","unstructured":"Salem JE, Ederhy S, Lebrun-Vignes B, Moslehi JJ. Cardiac Events Associated With Chimeric Antigen Receptor T-Cells (CAR-T): A VigiBase Perspective. J Am Coll Cardiol. 2020;75:2521\u20133. https:\/\/doi.org\/10.1016\/j.jacc.2020.02.070.","journal-title":"J Am Coll Cardiol"},{"key":"1791_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jaccao.2026.01.005","volume":"8","author":"B Itzhaki","year":"2026","unstructured":"Itzhaki B, Zadok O, et al. Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy. JACC CardioOncol. 2026;8:152\u201364. https:\/\/doi.org\/10.1016\/j.jaccao.2026.01.005.","journal-title":"JACC CardioOncol"},{"key":"1791_CR19","doi-asserted-by":"publisher","first-page":"S961","DOI":"10.1016\/S2152-2650(25)02678-3","volume":"25","author":"S Lakshmi","year":"2025","unstructured":"Lakshmi S, Meghana K, et al. MM-1053: Cardiovascular Risk of CAR T-Cell and Bispecific Immunotherapies in Relapsed or Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis. Clin Lymphoma Myeloma Leuk. 2025;25:S961. https:\/\/doi.org\/10.1016\/S2152-2650(25)02678-3.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1791_CR20","doi-asserted-by":"publisher","first-page":"8091","DOI":"10.1182\/blood-2025-8091","volume":"146","author":"R Harshawardhan Dhanraj","year":"2025","unstructured":"Harshawardhan Dhanraj R, et al. Cardiovascular adverse events associated with bispecific antibodies in Relapsed\/Refractory hematologic malignancies: A comprehensive systematic review and meta-analysis. Blood. 2025;146:8091. https:\/\/doi.org\/10.1182\/blood-2025-8091.","journal-title":"Blood"},{"key":"1791_CR21","doi-asserted-by":"publisher","first-page":"24782","DOI":"10.1038\/s41598-025-03391-z","volume":"15","author":"C Shan","year":"2025","unstructured":"Shan C, et al. Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T cell engagers in multip myeloma. Sci Rep. 2025;15:24782. https:\/\/doi.org\/10.1038\/s41598-025-03391-z.","journal-title":"Sci Rep"},{"key":"1791_CR22","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:1403\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(21)00375-2.","journal-title":"Lancet Oncol"},{"key":"1791_CR23","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2022018893","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307\u201315. https:\/\/doi.org\/10.1182\/blood.2022018893.","journal-title":"Blood"},{"key":"1791_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7.","journal-title":"Lancet Oncol"},{"key":"1791_CR25","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382:1331\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1914347.","journal-title":"N Engl J Med"},{"key":"1791_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol. 2023;41:555\u201367. https:\/\/doi.org\/10.1200\/JCO.21.02370.","journal-title":"J Clin Oncol"},{"key":"1791_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(21)01222-8.","journal-title":"Lancet"},{"key":"1791_CR28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0.","journal-title":"Lancet"},{"key":"1791_CR29","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"key":"1791_CR30","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398:665\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(21)01338-6.","journal-title":"Lancet"},{"key":"1791_CR31","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study. Lancet Haematol. 2025;12:e269\u201381. https:\/\/doi.org\/10.1016\/S2352-3026(24)00385-5.","journal-title":"Lancet Haematol"},{"key":"1791_CR32","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"A Goldman","year":"2021","unstructured":"Goldman A, et al. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. J Am Coll Cardiol. 2021;78:1800\u201313. https:\/\/doi.org\/10.1016\/j.jacc.2021.08.044.","journal-title":"J Am Coll Cardiol"},{"key":"1791_CR33","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40259-025-00735-z","volume":"39","author":"T Shastri","year":"2025","unstructured":"Shastri T, Trabolsi A, Arumov A, H Schatz J. Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline. BioDrugs. 2025;39:793\u2013814. https:\/\/doi.org\/10.1007\/s40259-025-00735-z.","journal-title":"BioDrugs"},{"key":"1791_CR34","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review. JAMA. 2024;332:1924\u201335. https:\/\/doi.org\/10.1001\/jama.2024.19462.","journal-title":"JAMA"},{"key":"1791_CR35","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi RM, et al. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). J Am Coll Cardiol. 2019;74:3099\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.038.","journal-title":"J Am Coll Cardiol"},{"key":"1791_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","volume":"31","author":"MW Bloom","year":"2025","unstructured":"Bloom MW, et al. Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America. J Card Fail. 2025;31:415\u201355. https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.045.","journal-title":"J Card Fail"},{"key":"1791_CR37","doi-asserted-by":"publisher","first-page":"1601808","DOI":"10.3389\/fonc.2025.1601808","volume":"15","author":"H Du","year":"2025","unstructured":"Du H, Wang J, Wang Z. Cardiovascular adverse effects of immunotherapy in cancer: insights and implications. Front Oncol. 2025;15:1601808. https:\/\/doi.org\/10.3389\/fonc.2025.1601808.","journal-title":"Front Oncol"},{"key":"1791_CR38","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","volume":"44","author":"SS Mahmood","year":"2023","unstructured":"Mahmood SS, et al. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Eur Heart J. 2023;44:2029\u201342. https:\/\/doi.org\/10.1093\/eurheartj\/ehad117.","journal-title":"Eur Heart J"},{"key":"1791_CR39","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1002\/ejhf.3753","volume":"27","author":"A Rakisheva","year":"2025","unstructured":"Rakisheva A, et al. Prevention of cancer therapy-related cardiac dysfunction and heart failure in cancer patients and survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology. Eur J Heart Fail. 2025;27:2084\u201399. https:\/\/doi.org\/10.1002\/ejhf.3753.","journal-title":"Eur J Heart Fail"},{"key":"1791_CR40","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1161\/CIR.0000000000001174","volume":"148","author":"D Addison","year":"2023","unstructured":"Addison D, et al. Cardiovascular Imaging in Contemporary Cardio-Oncology: A Scientific Statement From the American Heart Association. Circulation. 2023;148:1271\u201386. https:\/\/doi.org\/10.1161\/CIR.0000000000001174.","journal-title":"Circulation"},{"key":"1791_CR41","doi-asserted-by":"publisher","first-page":"924208","DOI":"10.3389\/fonc.2022.924208","volume":"12","author":"LR Chen","year":"2022","unstructured":"Chen LR, et al. Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis. Front Oncol. 2022;12:924208. https:\/\/doi.org\/10.3389\/fonc.2022.924208.","journal-title":"Front Oncol"},{"key":"1791_CR42","doi-asserted-by":"publisher","unstructured":"Liu Y, et al. Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells. J Transl Med. 2025;23. https:\/\/doi.org\/10.1186\/s12967-024-06035-4.","DOI":"10.1186\/s12967-024-06035-4"},{"key":"1791_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjh.70216","volume":"208","author":"B Itzhaki","year":"2026","unstructured":"Itzhaki B, Zadok O, et al. Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy. Br J Haematol. 2026;208:239\u201349. https:\/\/doi.org\/10.1111\/bjh.70216.","journal-title":"Br J Haematol"},{"key":"1791_CR44","doi-asserted-by":"publisher","first-page":"e24019","DOI":"10.1200\/JCO.2025.43.16_suppl.e24019","volume":"43","author":"A Jafar","year":"2025","unstructured":"Jafar A, et al. Cardiovascular complications of patients receiving CAR-T therapy. J Clin Oncol. 2025;43:e24019\u201324019. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e24019.","journal-title":"J Clin Oncol"},{"key":"1791_CR45","doi-asserted-by":"publisher","first-page":"e14503","DOI":"10.1200\/JCO.2025.43.16_suppl.e14503","volume":"43","author":"D Tai","year":"2025","unstructured":"Tai D, et al. Meta-analysis of the cardiovascular adverse effects of bispecific antibodies in malignant hematology therapies. J Clin Oncol. 2025;43:e14503\u201314503. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e14503.","journal-title":"J Clin Oncol"},{"key":"1791_CR46","doi-asserted-by":"publisher","first-page":"1348955","DOI":"10.3389\/fimmu.2024.1348955","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Zhao A, Zhu J, Niu T. Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials. Front Immunol. 2024;15:1348955. https:\/\/doi.org\/10.3389\/fimmu.2024.1348955.","journal-title":"Front Immunol"},{"key":"1791_CR47","doi-asserted-by":"publisher","unstructured":"Liang X, et al. Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-010064.","DOI":"10.1136\/jitc-2024-010064"},{"key":"1791_CR48","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41408-025-01334-5","volume":"15","author":"M Golmohammadi","year":"2025","unstructured":"Golmohammadi M, et al. Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma. Blood Cancer J. 2025;15:130. https:\/\/doi.org\/10.1038\/s41408-025-01334-5.","journal-title":"Blood Cancer J"},{"key":"1791_CR49","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/14740338.2025.2470875","volume":"24","author":"X Le","year":"2025","unstructured":"Le X, Zhang Y, Ma J. Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database. Expert Opin Drug Saf. 2025;24:821\u201330. https:\/\/doi.org\/10.1080\/14740338.2025.2470875.","journal-title":"Expert Opin Drug Saf"},{"key":"1791_CR50","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12935-023-03045-y","volume":"23","author":"M Noori","year":"2023","unstructured":"Noori M, Yazdanpanah N, Rezaei N. Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis. Cancer Cell Int. 2023;23:193. https:\/\/doi.org\/10.1186\/s12935-023-03045-y.","journal-title":"Cancer Cell Int"},{"key":"1791_CR51","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384:705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"key":"1791_CR52","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8.","journal-title":"Lancet"},{"key":"1791_CR53","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022;387:2232\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2204591.","journal-title":"N Engl J Med"},{"key":"1791_CR54","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376:836\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1609783.","journal-title":"N Engl J Med"},{"key":"1791_CR55","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;387:2220\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2206913.","journal-title":"N Engl J Med"},{"key":"1791_CR56","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial. J Clin Oncol. 2023;41:2238\u201347. https:\/\/doi.org\/10.1200\/JCO.22.01725.","journal-title":"J Clin Oncol"},{"key":"1791_CR57","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(22)00335-7.","journal-title":"Lancet Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01791-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01791-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01791-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:15:32Z","timestamp":1785518132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01791-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1791"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01791-6","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to correct the presentation and layout of Box 1.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Generative AI and AI-assisted technologies were not used in the preparation of this manuscript.","order":1,"name":"Ethics","label":"AI Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"67"}}